SIRT3 and persistent truncus arteriosus: NaHS, an H2S donor, is a potential treatment for transverse aortic constriction (TAC)-induced myocardial fibrosis and Ang II-induced cardiac fibroblast proliferation by enhancing SIRT3 levels.